文章摘要
环泊酚复合布托啡诺在无痛胃镜检查中的最佳剂量组合
Optimal dose combination of ciprofol combined with butorphanol in painless gastroscopy
  
DOI：10.12089/jca.2025.04.011
中文关键词: 环泊酚  布托啡诺  无痛胃镜  析因分析  不良反应
英文关键词: Ciprofol  Butorphanol  Painless gastroscopy  Factorial analysis  Adverse reaction
基金项目:
作者单位E-mail
马欢 030001,太原市,山西医科大学第二医院麻醉科 1468067853@qq.com 
张林忠 030001,太原市,山西医科大学第二医院麻醉科  
赵利军 030001,太原市,山西医科大学第二医院麻醉科  
孔令春 030001,太原市,山西医科大学第二医院麻醉科  
毋楠 030001,太原市,山西医科大学第二医院麻醉科  
申宁 030001,太原市,山西医科大学第二医院病理科  
摘要点击次数: 255
全文下载次数: 40
中文摘要:
      
目的：探讨环泊酚复合布托啡诺用于无痛胃镜检查的最佳剂量组合。
方法：选择择期行无痛胃镜检查的患者300例，男154例，女146例，年龄18～84岁，ASA Ⅰ或Ⅱ级。采用随机数字表法，按不同剂量布托啡诺将患者随机分为三组：布托啡诺0.3 mg（B1）、布托啡诺0.4 mg（B2）、布托啡诺0.5 mg（B3），每组再按环泊酚剂量随机分为5个亚组：环泊酚0.3 mg/kg（C1）、环泊酚0.35 mg/kg（C2）、环泊酚0.4 mg/kg（C3）、环泊酚0.45 mg/kg（C4）、环泊酚0.5 mg/kg（C5），共15组，每组20例。记录诱导前、诱导后HR、SBP、DBP，进镜时间、环泊酚追加剂量、苏醒时间，检查过程中低血压、体动、呛咳、低氧血症等不良反应发生情况。
结果：15组诱导前、诱导后HR、SBP、DBP差异无统计学意义。B2C4、B2C5、B3C4、B3C5组进镜时间差异无统计学意义，较其余各组进镜时间明显缩短（P＜0.05）。B2C2、B2C3、B2C4、B2C5、B3C3、B3C4、B3C5组追加环泊酚剂量差异无统计学意义，较其余各组追加剂量明显减小（P＜0.05）。B2C3、B2C4、B3C3、B3C4组苏醒时间差异无统计学意义，较其余各组苏醒时间明显缩短（P＜0.05）。布托啡诺与环泊酚的交互作用或单独作用都会影响进镜时间和苏醒时间（P＜0.05），布托啡诺与环泊酚的交互作用或环泊酚的单独作用会影响环泊酚追加剂量（P＜0.05）。B1C5、B2C4组较其余各组总不良反应发生率明显降低（P＜0.05）。
结论：布托啡诺0.4 mg复合环泊酚0.45 mg/kg药物配比在胃镜检查时进镜时间短、追加环泊酚剂量小、苏醒时间短且不良反应少。
英文摘要:
      
Objective: To investigate the optimal dose combination of ciprofol combined with butorphanol in painless gastroscopy.
Methods: A total of 300 patients, 154 males and 146 females, aged 18-84 years, ASA physical status Ⅰ or Ⅱ, were selected to undergo painless gastroscopy. Using random number table method, 300 patients were randomly divided into three groups according to different doses of butorphanol 0.3 mg (B1), butorphanol 0.4 mg (B2), butorphanol 0.5 mg (B3), and each group was randomly divided into 5 subgroups according to different doses of ciprofol: ciprofol 0.3 mg/kg (C1), ciprofol 0.35 mg/kg (C2), ciprofol 0.4 mg/kg (C3), ciprofol 0.45 mg/kg (C4), and ciprofol 0.5 mg/kg (C5) were divided into 15 groups, with 20 patients in each group. HR, SBP, DBP before and after induction, time of admission, additional dosage of ciprofol, time of recovery, hypotension, movement, coughing, hypoxemia, and other adverse effects occurred during the examination were recorded and analyzed.
Results: There were no significant differences in HR, SBP, DBP among the fifteen groups before and after induction. There were no significant differences in time of admission among groups B2C4, B2C5, B3C4, and B3C5, however, time of admission was significantly shorter compared with the other groups (P < 0.05). There were no significant differences in the additional dosage of ciprofol among the groups B2C2, B2C3, B2C4, B2C5, B3C3, B3C4, and B3C5, however, the additional dose of ciprofol was significantly lower compared with the other groups (P < 0.05). There were no significant differences in recovery time among the groups B2C3, B2C4, B3C3, and B3C4, however, recovery time was significantly shorter compared with the other groups (P < 0.05). The interaction or alone effect of butorphanol and ciprofol will affect the admission time and recovery time of patients (P < 0.05). The interaction of butorphanol and ciprofol or the alone effect of ciprofol will affect the additional dosage of ciprofol. The incidence of adverse reactions was significantly lower in groups B1C5 and B2C4 compared with the other groups (P < 0.05).
Conclusion: Butorphanol 0.4 mg combined with ciprofol 0.45 mg/kg has short entry time, small dosage of additional ciprofol, short recovery time and few adverse reactions.
查看全文   查看/发表评论  下载PDF阅读器
关闭